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 Abstract 
 
	
 Osteosarcomas are the main malignant primary bone tumours found in children 
and young adults. Conventional treatment is based on diagnosis and resection surgery, 
combined with polychemotherapy. This is a protocol that was established in the 1970s. 
Unfortunately, this therapeutic approach has reached a plateau of efficacy and the patient 
survival rate has not improved in the last four decades. New therapeutic approaches are thus 
required to improve the prognosis for osteosarcoma patients. 
 
From the databases available and published scientific literature, the present 
review gives an overview of the drugs currently in early clinical development for the 
treatment of osteosarcoma. For each drug, a short description is given of the relevant 
scientific data supporting its development.  
		
Multidrug targeted approaches are set to emerge, given the heterogeneity of 
osteosarcoma subtypes and the multitude of therapeutic responses. The key role played by the 
microenvironment in the disease increases the number of therapeutic targets (such as 
macrophages or osteoclasts), as well as the master proteins that control cell proliferation or 
cell death. Ongoing phase I/II trials are important steps, not only for identifying new therapies 
with greater safety and efficacy, but also for better defining the role played by the 
microenvironment in the pathogenesis of osteosarcoma. 
 
Key words: Clinical Trials, Immunotherapy, Macrophages, Microenvironment, 
Osteosarcoma, Immunomodulation, Cancer+Initiating Cells 
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Article highlights 
 
• Tumour microenvironment is a key modulator in osteosarcoma development and is the 
source of new therapeutic targets 
• Immunomodulators are promising drugs for controlling refractory and recurrent 
osteosarcoma (e.g. anti+GD2 therapy) 
• Bone cells and bone matrix are two potential new targets for osteosarcoma (e.g. the 
anti+RANKL antibody, radium+223) 
• Nanomedicine has led to the development of a new generation of compounds from 
“old” drugs (e.g. Nab+paclitaxel) 
• Large biological cohorts with relevant clinical annotations are essential for rare 
tumours and will be an important source of new therapeutic targets  
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1. General features of osteosarcoma 
 
Osteosarcoma accounts for 50% of all bone sarcomas, and is the most frequent primary 
malignant tumour found in children and young adults. With a peak of incidence at around 18 
years, the male/female sex ratio is 1:4. A second peak of incidence is described in the elderly 
following radiotherapy, or in conjunction with Paget disease. The metaphyses of the long 
bones are their preferred development site. The proximal end of the tibia or humerus, as well 
as the distal end of the femur, is frequently affected. Sixty per cent of all cases of 
osteosarcoma are detected in the knee [1,2]. 
Osteosarcoma is part of a large family of heterogeneous histological tumour entities of 
mesenchymal origin [3+9]. It expresses osteoblastic markers such as the runx2 master gene, 
alkaline phosphatase, osteocalcin or bone sialoprotein [10,11]. As a result, it has now been 
recognized that conventional osteoblastic osteosarcoma cells originate from a mesenchymal 
cell or committed osteoblast in which an initial oncogenic event occurs, followed by 
secondary genetic alterations [12]. Osteosarcomas are bone forming tumours associated with 
an osteolytic component which defined according its intensity: osteoblastic, osteolytic or 
mixed tumour entities. Osteosarcoma is thus a genetically complex disease. A recent study 
analysing a series of 44 osteosarcoma patients perfectly illustrates their high level of 
heterogeneity and complexity [13]. As expected, these authors demonstrated recurrent  
and  somatic alterations and identified 84 point mutations and 4 deletions related to 82 
different genes [13]. Similarly, Kovacs 	
  studied the genetic alterations of 31 
osteosarcomas and demonstrated that more than 80% of the cases could be explained by the 
fact that they exhibited a specific combination of single+base substitutions, a loss of 
heterozygosity, or large+scale genome instability. They identified alterations in 14 driver 
genes (
 , , , , , , , , 
 , 
,  and  with signatures characteristic of BRCA1/2+deficient tumours 
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[14]. They also proposed a new model for osteosarcoma development in which a  and/or 
 mutant cell initiated a monoclonal disease. This cell population exhibited higher 
chromosomic instability, leading to both the emergence of new cell clones and polyclonal 
disease associated with these secondary genetic events [14]. The combination of multiple 
genetic events and a favourable microenvironment facilitate tumour growth [15+20]. It has 
been hypothesised that this microenvironment may be a sanctuary that sustains cell dormancy 
and contributes to drug resistance [20+22].  
As osteosarcomas are bone+forming tumours, one of their signatures is the presence of 
osteoid tissue in close contact with spindle tumour cells. The morphology and organisation of 
tumour cells (such as extracellular matrix components) make it possible to identify various 
tumour subtypes, including osteoblastic, fibroblastic, chondroblastic, and highly vascularised 
telangiectactic forms, as well as giant cell enriched tumours [3+11]. Osteosarcomas are 
particularly prone to inducing lung metastases, which occur within 36 months of diagnosis 
and which have a strong impact on patient survival rate. Bone metastases can also occur in 
osteosarcoma, and they are associated with a worse survival rate than lung metastases [23]. 
The survival rate is estimated at around 50+70% after 5 years for non+metastatic patients and 
decreases dramatically to 30% when lung metastases are detected at the time of diagnosis 
(around 20% of patients) [24,25]. Unfortunately, these values have not changed in the last 
four decades [24]. The aim of the present review is to provide an overview of the main 
therapeutic approaches currently in development in the treatment of osteosarcoma. 
 
2. Conventional therapeutic approaches to osteosarcoma 
The therapeutic protocol currently in use for osteosarcoma was established by Rosen 	
. at 
the end of the 1970s. It is a multimodal approach that combines surgery and 
polychemotherapy [26]. The advantages of chemotherapy were established by Link 	
 in a 
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randomised clinical trial that compared surgery with postoperative chemotherapy, and surgery 
alone [27]. Chemotherapy can be administered before (pre+operative, or neo+adjuvant, 
chemotherapy) and/or after surgery (post+operative, or adjuvant, chemotherapy). Overall, the 
duration of the chemotherapy is around 6 to 12 months and combines doxorubicin, cisplatin, 
methotrexate and ifosfamide which are among the most efficient chemotherapeutic agents that 
have been identified for osteosarcoma [28]. The European Osteosarcoma Intergroup carried 
out a retrospective study of several clinical trials analysing various drug combinations and 
demonstrated the advantages of combining at least three drugs (reference combination: 
doxorubicin + methotrexate + cisplatin), and concluded that the doxorubucin/cisplatin 
association should no longer be considered as the standard chemotherapy combination for 
patients aged under 40 years with localised resectable osteosarcoma [29]. In addition, they 
demonstrated that chemotherapy+induced toxicity was a prognosis for overall survival, with 
the presence of greater toxicity generally associated with better survival [30]. However, 
although the advantages of neo+adjuvant chemotherapy have not been demonstrated [31], it is 
beneficial in several ways in treatment: i) it makes possible better delineation of tumours due 
to the formation of avascular collagenous pseudocaspules and then facilitates the definition of 
the surgical margin, ii) it reduces local tumour recurrence rates, iii) it makes it possible to 
evaluate the therapeutic response by means of histology, iv) it facilitates the preparation of 
definitive surgery for limb+salvage procedures by gaining time [32]. The Huvos grading 
system defines the therapeutic response and is established for the resected tumour, scoring the 
percentage of residual viable tumour cells (grade I >50%; grade II from 11 to 50 %; grade III 
from 1 to 10%; grade IV: no viable cells detected) [33]. Patients graded III and IV are 
considered to be good responders, and those graded I and II to be poor responders. As with a 
poor histological response, inadequate surgical margins are also an additional risk factor for 
local recurrence. The quality of the tumour resections, as evaluated by the quality of the 
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surgical margins, is correlated with a high risk of local recurrence [34,35]. Unfortunately, at 
present, there is no consensus for staging and comparing these margins between all 
surgical/pathological teams. Although this histological assessment is a key parameter in 
patient follow+up, the key challenge has been to determine whether the modification to post+
operative treatment according to the therapeutic response analysed after the neo+adjuvant 
chemotherapy can improve the patients’ therapeutic response [36]. The European and 
American Osteosarcoma Study Group (EURAMOS), composed of the Children’s Oncology 
Group (COG), the Cooperative Osteosarcoma Study Group (COSS), the European 
Osteosarcoma Intergroup (EOI), and Scandinavian Sarcoma Group (SSG), analysed the 
impact of the nature of post+chemotherapy on 2,260 registered patients (good and poor 
responders) [37]. In a large clinical trial called EURAMOS+1, they compared the therapeutic 
advantages of MAP (Methotrexate/Doxorubicin/Cisplatin) and MAPIE 
(MAP/Ifosfamide/Etoposide) in poor responders, and MAP and MAPinf (MAP/Interferon+α) 
in good responders. In poor responders, MAP  ! MAPIE therapy did not show any difference 
in event+free survival [38]. Similarly, in good responders, MAPInf was not statistically 
different from MAP alone [39]. Overall, these results do not support adaptation of post+
operative chemotherapy based on histological response. Osteosarcoma tumours are 
notoriously radioresistant [39]. However radiotherapy is used when adequate surgery is 
impossible, such as when the tumour is located in a high risk area (e.g. spine, pelvis, head and 
neck) [41,42]. Radiotherapy can thus help to sterilize microscopic margins, and then 
contribute to local control of osteosarcoma growth in patients in whom surgical resection 
cannot lead to negative margins [43]. In addition, radiotherapy is a useful palliative tool for 
paediatric patients, especially when it comes to controlling bone pain [44]. 
 
3. Multi target drugs and osteosarcoma 
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The poor results obtained with conventional therapeutic approaches led to the exploration of 
new, more effective treatments with less toxicity [45+47] (Figure 1). In this context, numerous 
clinical trials have been proposed, directly targeting cancer cells and/or their 
microenvironment. Insulin+like growth factor+1 (IGF+1) and its receptor (IGF1+R) are 
expressed by osteosarcoma cells [48]. IGF+1 expression has been associated with the 
aggressiveness of the disease [48], However, IGF+1R status had no effect on median 
progression+free survival [50]. Based on this observation and an abundant literature exploring 
the advantages of blocking IGF+1 signalling in preclinical models, clinical trials targeting 
IGF+1 signalling using anti+IGF+1 or anti+IGF1R were set up [45]. Anti+IGF1+R antibodies 
were well+tolerated, although an extremely limited number of tumour responses were reported 
when it was used as a single or combined therapy [51]. These results can be explained by the 
existence of alternative signalling pathways that control cell proliferation [52], and/or by 
therapeutic escape through activation of phospho+AKT [53]. However, sirolimus, an mTOR 
inhibitor, has been identified as being a potentially interesting compound in osteosarcoma 
[54]. A phase I clinical trial [NCT02517918, “Metronomic chemotherapy in patients with 
advanced solid tumours with bone metastasis and advanced pretreated osteosarcoma 
(METZOLIMOS)”, 2015+2017, patients >13 years old] has been started. This study will 
include patients with unresectable locally advanced or metastatic osteosarcoma. The 
maximum tolerated dose is the primary outcome when sirolimus is administered in 
combination with cyclophosphamide, methotrexate and zoledronic acid. 
Numerous cytokines and growth factors act through activation of receptor tyrosine 
kinases (RTKs) and control cell proliferation, survival and migration [55]. Therefore, most of 
the RTK inhibitors (e.g. imatinib mesylate, dasatinib, sunitinib) considered to be multi+target 
therapies were assessed, although unfortunately their efficacy was low [55+65]. Pazotinib, 
which targets VEGFR, PDGFR and c+KIT [61,62], and sorafenib, which targets RET and 
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VEGFR, show benefits in paediatric bone sarcomas by affecting angiogenesis [63,64]. Sofwat 
	
. reported significant clinical responses in three metastatic osteosarcoma patients treated 
with 800 mg of oral pazopanib daily [62]. Clinical trials recruiting a significant number of 
patients are in progress to confirm the initial data obtained (Table 1). Grignani 	
. studied 
the therapeutic effects of sorafenib in relapsed and unresectable high+grade osteosarcoma 
(clinical trial ref. NCT00889057, 35 patients) [64]. Thirty+five young and adult patients were 
enrolled and treated with 400 mg of sorafenib twice daily until progression or unacceptable 
toxicity. Sorafenib demonstrated activity as a second+ or third+line treatment in terms of 
progression+free survival at 4 months, however the main limitation of this study was the lack 
of a control group. Associating sorafenib with everolimus did not produce any significant 
additional benefit compared to sorafenib alone [64]. Similarly, regorafenib is an oral 
multikinase inhibitor of angiogenic (VEGFR1+3, TIE2), stromal (PDGFR+β, FGFR), and 
oncogenic kinases (KIT, RET, and RAF). A phase I clinical trial revealed preliminary 
evidence of antitumor activity in patients with solid tumours including osteosarcoma [65]. A 
phase II trial started in 2014 is currently in the recruitment phase (Table 1). 
c+MET (Mesenchymal Epithelial Transition) and its ligand hepatocyte growth factor 
are involved in many pathophysiological processes, especially in oncology. c+MET is a 
tyrosine kinase receptor encoded by the MET proto+oncogene and induces signalling 
pathways involving PI3K/Akt, MAPK and NFκB. Its transforming activity was initially 
identified in osteosarcoma cells and named MNNG HOS transforming gene [66]. Both 
proteins are expressed by musculoskeletal tumours [67], and osteosarcomas exhibit aberrant 
expression of the receptor [68+70]. In a preclinical model, c+Met inhibition reduced 
osteosarcoma growth, dysregulated bone remodelling [71], and sensitised cancer cells to 
chemotherapy [72]. These observations were the justification for setting up a phase II clinical 
trial using cabozantinib, a c+MET inhibitor (NCT02243605, “Cabozantinib+s+malate in 
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treating patients with relapsed osteosarcoma or Ewing sarcoma”). Enrolment of 90 patients (> 
12 years old) treated for relapsed osteosarcoma started in December 2014. The final data will 
be collected in June 2016 for the primary outcome measure. Dose use in sarcomas 
corresponds to 60 mg tablets taken orally once a day in a 28+day cycle, repeated every 28 
days in the absence of disease progression or toxicity. The primary outcome will be the 
antitumour activity of cabozantinib, in terms of 6+month objective response (complete 
response, partial response) and 6+month non+progression. 
 
4. Targeting the bone microenvironment 
Osteosarcoma cells are able to dysregulate the bone microenvironment by activating 
osteoclast differentiation and resorption, which in turn stimulate tumour growth by releasing 
proliferative factors stored in the extracellular matrix [17]. A vicious cycle is thus established 
between osteosarcoma and bone cells that identify osteoclasts as a potentially interesting 
target in bone sarcoma [73,74]. Preclinical investigations demonstrated that nitrogen+
containing bisphosphonates decreased the proliferation of osteosarcoma cell lines "#
 "	$%
and 
induced cell death [75,76]. In murine models, zoledronic acid decreased the volume of the 
primary tumour [77,78] and also the number of lung metastases induced [79,80]. In addition, 
combining it with chemotherapy revealed its value with regard to improving tissue repair and 
preventing tumour recurrence [81]. The mechanisms of action of zoledronic acid can be 
explained by its pleiotropic effects on osteosarcoma, especially modulating angiogenesis, and 
the bone and immune environment [82]. However, in 2010, Endo+Munoz 	
. brought into 
question the therapeutic advantages of zoledronic acid, showing that a blockade of 
osteoclastogenesis played a part in the development of osteosarcoma lung metastases [83]. A 
phase III clinical trial called OS2006 (NCT00470223, “Combined chemotherapy with or 
without zoledronic acid for patients with osteosarcoma”) enrolled 318 patients (children and 
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adults). This clinical trial was stopped prematurely due to the absence of any significant 
difference between the groups with or without zoledronic acid [84]. Various hypotheses can 
be advanced, including: i) the development of a resistance mechanism associated with 
farnesyl diphosphate synthase in long+term treatment with zoledronic acid [85]; ii) the 
development of drug resistance due to the emergence of stemness properties in treated cancer 
cells [86]. A phase I clinical trial is in progress associating sirolimus with cyclophosphamide, 
methotrexate and zoledronic acid (NCT02517918, see paragraph 3). In addition to monocyte 
lineage, γ9δ2 T cells are key targets for zoledronic acid [87,88]. By inducing the release of 
phosphor+antigens, zoledronic acid induces the proliferation of these T lymphocytes. 
Interestingly, osteosarcoma cells are sensitised to zoledronic acid [89]. Using it to amplify &

 " %
 γ9δ2 T cells and sensitise osteosarcoma to the immune response may be a future 
treatment possibility. Based on an immonuregulatory effect, a phase I clinical trial is due to 
study the safety of transplantation with a haploidentical donor’s peripheral blood stem cell 
graft depleted of TCRαβ
+
 cells and CD19
+
 cells, in conjunction with zoledronic acid 
(NCT02508038, 21 patients, 2016+220, recruiting). 
RANKL (Receptor Activator of Nuclear Factor Factor kappeB) and its receptor 
RANK clearly control osteoclast differentiation/activation, and consequently bone 
remodelling [90]. RANK is not only expressed by monocyte lineage (e.g. macrophages, 
dendritic cells, osteoclasts) and by endothelial cells, it is also expressed by osteosarcoma 
cells, as revealed by RT+qPCR and immunostaining. Depending on the series published, 18 to 
69% of osteosarcoma cells express RANK [91+93]. A reverse correlation between RANK 
expression and the overall survival of patients with osteosarcoma has been demonstrated, but 
not with the response to chemotherapy [92]. Similarly, Bago+Horvath 	
 .
 reported that 
RANK expression is a negative prognostic factor for disease+free survival [93]. RANKL is 
also expressed by osteosarcoma cells [94,95]. One recent report has ignited controversy 
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regarding the role of RANK/RANKL in the pathogenesis of osteosarcoma [95]. These authors 
did not detect the presence of RANK in osteosarcoma samples, and concluded that autocrine 
RANKL/RANK signalling in human osteosarcomas may not be operative, and anti+RANKL 
therapy may not directly affect the tumour [95]. This discrepancy may be explained by the 
decalcification methods used and also by the source of the antibodies. Preclinical 
investigations demonstrated that RANKL blockade by osteoprotegerin, or soluble RANK 
delivery, has a strong impact on tumour development [96+98]. In other cancer cell types, 
tumour+infiltrating regulatory T cells appear to be the main source of RANKL, and may be a 
strong regulator of local immunity [99]. Denosumab is a fully humanised antibody that blocks 
RANKL binding to RANK and its functional activities [100]. In 2015, in a RANKL/RANK 
positive tumour, Cathomas 	
. reported complete metabolic remission for over 18 months 
after treatment with combined sorafenib and denosumab, in a patient with progressive 
osteosarcoma after two lines of chemotherapy and radiotherapy [101]. A phase II clinical trial 
was thus initiated in 2015 led by the Children’s Oncology Group (NCT02470091, 
“Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma”). Ninety 
patients (age range: 11 to 50 years) who have relapsed or become refractory to conventional 
therapy with a regimen including some combination of high dose methotrexate, doxorubicin, 
cisplatin, ifosfamide and etoposide, will be included. Two cohorts will be formed: cohort I, 
patients with measurable disease according to RECIST, and cohort II, patients with complete 
resection of all sites of metastatic disease within 30 days prior to enrolment. Each patient will 
receive denosumab s.c. on day 1 (days 1, 8, and 15 in the first course of treatment). The 
treatment will be repeated every 4 weeks (28 days) for up to 24 months or 26 courses, 
whichever occurs first, in the absence of disease progression or unacceptable toxicity. At the 
end of the course of treatment, patients will be followed up for 3 years. The primary 
outcomes will be: i) the disease control rate at 4 months (cohort I), compared to historical 
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Children’s Oncology Group experience with an objective response rate greater than 5%; ii) 
the disease control rate at 12 months, compared to historical Children’s Oncology Group 
experience (cohort II); iii) and the RECIST response at 4 months, compared to historical 
Children’s Oncology Group experience with an objective response rate greater than 5%. The 
final data collection date for the primary outcome measure is April 2019. Secondary 
objectives include: i) investigation of pharmacokinetics and pharmacodynamics; ii) 
description of the tolerability of denosumab; iii) a review of the disease control rate and 
objective response rate for patients with recurrent osteosarcoma restricted to bone; iv) 
investigation of the biological markers associated with the therapeutic response to 
denosumab.  
 
5. Immunomodulating drugs and osteosarcoma 
Several reports have underlined the therapeutic value of using immunotherapies or 
immunomodulatory+based therapies for osteosarcoma (see reviews [102+105]). Clinical 
investigations in osteosarcoma dogs gave impressive evidence of their efficacy and 
strengthened the interest of immunotherapies in human pathology [106+112]. In this context, 
the number of new drugs activating the immune system has exploded in the last 10 years and 
numerous phase I and II clinical trials are in progress in osteosarcoma. 
 
5.1. Mifamurtide (L MTP PE) 
Mifamurtide is a synthetic analogue of a bacterial cell wall component and is a potent 
activator of the immune response, especially macrophages. It was used alone and in 
combination with chemotherapy [113,114]. This immunomodulator improved overall survival 
from 70 to 78% (p=0.03) in combination with chemotherapy, and resulted in a one+third 
reduction in the risk of death from osteosarcoma [1115,116]. Mifamurtide was denied 
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approval by the U.S. Food and Drug Administration (FDA) in 2007 and authorised by the 
European Medicines Agency (EMA) in 2009. The therapeutic efficacy of Mifamurtide is not 
universally accepted but is included in the treatment of osteosarcoma patients in the UK, 
Spain, Turkey, Israel, Mexico and other countries in Europe, Asia and South America 
[117,118].L+MTP+PE stimulates both the macrophages’ cytotoxic function and the secretion 
of high numbers of soluble mediators, including TNF, IL+1, IL+6 or IL+8 which stimulate the 
angiogenesis and development of metastases [119]. In a phase II trial, Kleinerman et al 
demonstrated that Mifamurtide induced the infiltration of macrophages into patient 
osteosarcoma lung metastases and that these macrophages were "activated" macrophages 
[120]. Furthermore, there was also a significant difference in both progression+free and 
overall survival patient treated with Mifamurtide [121]. The density of tumour+associated 
macrophages seems to be a key biological parameter and is linked to poor prognosis. In 
osteosarcoma, Buddingh 	
 showed that macrophages exhibit M1 and M2 phenotypes and 
demonstrated a link between M2 macrophages and angiogenesis [122]. Similarly, in 
preclinical models of osteosarcoma, the recruitment of the M2 subtype is correlated with 
tumour angiogenesis and lung metastasis [123]. However, these observations have not been 
linked with Mifamurtide and available clinical data support the therapeutic benefit of this 
molecule in newly diagnosed osteosarcoma patients who present metastases [124].  Overall, 
these studies confirm the key role played by macrophages in the pathogenesis of 
osteosarcoma. The clinical investigations into the clinical benefits of mifamurtide continue, 
with an ongoing clinical trial combining mifamurtide and ifosfamide (Table 2). In 
osteosarcoma, around 50% of patients are poor responders to intensive conventional 
chemotherapy and these poor/no responses are frequently related to the over+expression of 
Multi+Drug Resistance protein+1 (MDR1 or P+gp for P+Glycoprotein or ABCB1). ABCB1 is 
also involved in the drug resistance mechanism associated with numerous compounds, 
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including certain protein kinase inhibitors which increase its expression [125]. Patient 
stratification of high+grade osteosarcoma patients was suggested in 2006 by Serra 	
. [126]. 
The effect of mifamurtide combined with chemotherapy will be re+evaluated in relation to 
ABCB1 expression. More than 200 non+metastatic patients will be included (ongoing 
recruitment, 2011+2020) in NCT014559484 trials in which overall survival will be the 
primary outcome (Table 2). Recently, Pahl 	
. observed that the induction of macrophage 
anti+tumour activity (M1 subtype) by mifamurtide required IFN+γ [127]. This approach may 
be highly relevant for optimising mifamurtide therapy in osteosarcoma patients, and may 
open up new opportunities for this drug even if the combination of interferon and 
chemotherapy has not revealed any significant difference compared to conventional 
chemotherapy alone [55].  
 
5.2. Disialoganglioside (GD2) 
In 1987, Heiner 	
 .
 described the preferential accumulation of an anti+GD2 monoclonal 
antibody (3F8, a murine IgG3) at the tumour site in a preclinical model of osteosarcoma 
similar to previous observations made in neuroblastoma [128]. Ten years later, a phase I 
clinical trial revealed that a human+mouse chimeric monoclonal antibody (mAb) ch 14.18 
directed against disialoganglioside (GD2) appeared to be clinically safe and effective with no 
specific toxicity after repeated administration [129]. An immunohistochemical study 
demonstrated that all the osteosarcoma tumours analysed were positive for GD2 in a series 
composed of 44 patients [130], and persisted upon recurrence [131]. '#
  "	$%, GD2 was 
suspected of enhancing the aggressiveness of the osteosarcoma [132]. Based on these 
observations, several clinical trials have been activated very recently (Table 2). Of them, one 
phase II trial (NCT02502786, sponsor: Memorial Sloan Kettering Cancer Center) will 
investigate the therapeutic advantages of the corresponding humanised form of the 3F8 
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antibody at a dose of 2.4mg/kg/dose for 3 days (days 1, 3, and 5) in the presence of GM+CSF. 
Patients (age range: 13 months+40 years) with recurrent high+grade osteosarcoma will be 
enrolled and the primary outcome will be event+free survival (time frame: 12 months) (Table 
2). Another phase II protocol referenced NCT02484443 (sponsor: National Cancer Institute; 
Children’s Oncology Group) is in progress and is studying the effects of a human+mouse anti+
GD2 monoclonal antibody ch14.18 in combination with sargramostim (GM+CSF) in patients 
with recurrent osteosarcoma (Table 2). Patients up to the age of 29 years will receive 
sargramostim s.c. on days 1+14 and dinutuximab i.v. over 20 hours on days 4 and 5 (the 
dinutuximab infusion can be extended for an additional 2 days for anticipated toxicities). The 
treatment will repeat every 28 days for up to 5 courses in the absence of disease progression 
or unacceptable toxicity. The primary outcome will be disease control after 12 months. The 
second type of clinical trial is based on T cell therapy. Activated T cells are armed with the 
OKT3/3F8 bispecific antibody and will be administered in combination with IL+2 and GM+
CSF (NCT02173093). GM+CSF is known to enhance the tumour antigen presentation by 
recruited mononuclear phagocytes and the functional coordination of CD4
+
 and CD8
+
 T cells. 
IL+2 participates to the maintenance of peripheral regulatory T cells (CD4
+
CD25
+
) and 
induces the proliferation of cytotoxic lymphocytes. The combination of GM+CSF, IL+2 and T 
cell activation by OKT3/3F8 which redirects T+cell cytolytic activity to cancer cells should 
improve the antitumour immune response. The first objective is to determine the maximum 
tolerated dose and to analyse its efficacy and side effects (Table 2). Interestingly, endothelin 
A receptor, which has been implicated in osteosarcoma progression and the metastatic 
process, potentiates the inhibitory effects of the anti+GD2 antibody on invasiveness and 
tumour cell viability, opening up new potential clinical investigations [133].   
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5.3. Nivolumab and Pembrozilumab 
Nivolumab and Pembrozilumab are immunomodulators which acts by blocking the activation 
of programmed cell death+1 (PD+1), induced by its ligand on subset activated T and pro+B 
lymphocytes [134]. PD+1 is part of the immunoglobulin superfamily that interacts with 
programmed cell death ligand 1 (PDL1), which is a cell+surface protein expressed in 
numerous cancer cells including osteosarcoma [135]. By interacting with PD+1, PDL+1 
induces inhibitory signalling and suppresses cytotoxic T+cell+mediated tumour responses 
[136,137]. PD+1 has a dual effect, promoting apoptosis in antigen+specific T lymphocytes 
located in lymph nodes, and decreasing apoptosis in regulatory T cells.Consequently, PD+1 
can be considered to be an immune checkpoint, down+regulating the immune system by 
preventing T lymphocyte activation. The inflammatory process in the tumour 
microenvironment is the source of many soluble factors such as IFN+γ, which may increase 
PDL+1 expression in cancer cells and suppress local immune responses [138]. Numerous 
preclinical investigations have demonstrated that inhibition of the interaction between PD+1 
and PD+L1 enhances the T+cell response, resulting in increased antitumour activity. However, 
the role of PD+L1 has not been formally demonstrated in patients even in diseases wherein the 
involvement of check+point inhibitors has been established (e.g. melanoma, non+small+cell 
lung cancer). Indeed, clinical benefits were described in patients whose cancer cells were 
PDL+1 negative, which raises new questions regarding the mechanism of action of this 
molecule [139]. A phase II study (Sarc028 trial) analysing the objective response rate in 
patients suffering from solid tumours including bone sarcomas and treated with 
pembrolizumab is in currently in progress (Table 2). A phase I/II trial will be concluded in 
2016 on refractory solid tumours and sarcomas, including osteosarcoma. 242 patients will be 
enrolled and treated with nivolumab IV over 60 minutes on days 1 and 15. Courses repeat 
every 28 days in the absence of disease progression or unacceptable toxicity (Table 2).  
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5.4. Immunity and dendritic cell vaccine 
Dendritic cells have the specific ability to initiate and modulate adaptive immune responses 
[140]. This specificity, associated with their role in antigen presentation, has led to their use in 
vaccine approaches to cancer. Matured autologous dendritic cells loaded with tumour lysates 
derived from tumour tissue were used as the vaccine product. In a pre+clinical model of 
osteosarcoma, it has been demonstrated that killer dendritic cells were able to induce an 
adaptive antitumour immune response with a decrease in tumour development after cross+
presentation of the tumour cell+derived antigen [141]. A phase I clinical trial demonstrated the 
feasibility and good tolerance of dendritic cells pulsed with MAGE+A1, MAGE+A3 and NY+
ESO+1 full length peptides in combination with decitabine. Antitumor activity was observed 
in some patients [142]. In 2012, 12 osteosarcoma patients were vaccinated with tumour lysate 
pulsed dendritic cells, but evidence of a clinical benefit was observed in only 2 of these 
patients [143]. These authors concluded that osteosarcoma patients may be relatively 
insensitive to DC+based vaccine treatments. A new clinical trial was initiated, enrolling 56 
patients (>1 year) with confirmed sarcoma, either relapsed or without known curative 
therapies, and treated with autologous dendritic cells pulsed with tumour lysate (Table 2). 
NCT02409576 is a pilot trial (“Pilot Study of Expanded, Activated Haploidentical Natural 
Killer Cell Infusions for Sarcomas (NKEXPSARC)”) analysing the effect of donor NK cells 
on clinical response determined by imaging. Twenty patients (aged 6 months to 80 years) will 
be included between 2015 and 2016. The patients will receive lymphodepleting chemotherapy 
with cyclophosphamide (1 day) followed by fludarabine (5 days) and each patient will receive 
IL+2 1 day before infusion of the NK cell (total 6 doses). 
 
6. Targeted alpha radiotherapy: Radium 223 
The principle of alpha radiotherapy is to induce double strand breaks in DNA [144]. Radium+
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223 (
223
Ra) is a bone+seeking alpha+emitter which has been studied extensively in preclinical 
models [145]. Its half+life is 11·4 days. Its biodistribution in mice revealed that bone matrix is 
its preferred location of retention. Radium+233 is well tolerated, with doses of 50–250 
kBq/kg, and has antitumour effects in preclinical murine models [146]. A first phase I clinical 
trial confirmed its potential clinical interest in skeletal metastases [147]. A recent phase III 
(NCT00699751) clinical trial in 921 patients with symptomatic castration+resistant prostate 
cancer with two or more bone metastases demonstrated the clinical benefit of radium+233 
therapy [148]. In light of the marked retention of radium+233 in the bone matrix, a phase I 
trial has been set up for osteosarcoma to determine the maximum tolerated dose 
(NCT018335201, “Phase I Dose Escalation of Monthly Intravenous Ra+223 Dichloride in 
Osteosarcoma”, 2013+2017, ongoing but not recruiting) in 15 patients (> 15 years). The phase 
I starting dose was 50 kBq/kg Ra+223 dichloride i.v. over several minutes on day 1 of each 4+
week cycle.
 
7. Alternative compounds for the treatment of osteosarcoma 
Numerous targeted therapies are due to be assessed in clinical trials (Table 3). Of these drugs, 
those using the signalling pathways or enzymes involved in the cell cycle appear particularly 
interesting. 
 
7.1. CC 115: a dual mTOR DNA protein dependent protein kinase inhibitor 
Optimisation of a series of triazoles led to the discovery of CC+115, which is able to both bind 
to mTOR and the DNA+protein dependent protein kinases involved in DNA repair 
mechanisms, and inhibit both of them [55,149]. CC+1115 inhibits both raptor+mTOR (TOR 
complex 1 or TORC1) and rictor+mTOR (TOR complex 2 or TORC2), and decreases the 
proliferation of cancer cells. DNA+PK is a serine/threonine kinase and from the PI3K+related 
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kinase family of protein kinases. DNA+PK is activated following DNA damage and is 
involved in repairing breaks in double+stranded DNA via the DNA nonhomologous end 
joining (NHEJ) pathway [150]. By inhibiting DNA+PK, CC+115 impacts the DNA+repair 
mechanisms of tumour cells, inhibits the proliferation of numerous cancer cell lines, and 
increases cell apoptosis [151]. CC+115 has an anti+tumour effect "#
 " %
as demonstrated by 
the inhibition of solid tumour growth in pre+clinical models of prostate cancer [149]. 
Interestingly, targeting DNA+PK increased the sensitivity of osteosarcoma cells to 
chemotherapeutic agents [152]. Treating cancer cells with CC+115 increases sensitivity to 
both chemo+ and radiotherapy. A phase I trial has been set up (NCT01353625) in which 144 
patients will receive increasing doses of oral CC+115 (starting with 0.5mg daily, in cycles of 
28 days) (Table 3). 
 
7.2. Abmaciclib: a CDK4 and CDK6 inhibitor 
Cell cycle progression is controlled by cyclin+dependent kinases (CDK), which are 
dysregulated in numerous cancer cells, leading to uncontrolled cell proliferation. Of the 
various kinases identified, CDK4 and related CDK6 play a part in the progression of cells into 
the DNA synthetic phase of the cell+division cycle. CDK4 and CDK6 act more specifically in 
the first gap phase (G1) of the cell cycle and they assemble with D+type cyclins (D1+D3) in 
response to various extracellular signals (i.e. mitigen activities and cytokine+induced 
signalling) to constitute enzymatically+active holoenzyme complexes [153]. Abmaciclib 
(LY2835219) is a CDK4 and CDK6 inhibitor capable of blocking the growth of cancer cells. 
Abemaciclib specifically inhibits CDK4/6 and related associated phosphorylation cascades 
such as Rb phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK+
mediated G1+S phase transition, blocking the cell cycle in the G1 phase, suppressing DNA 
synthesis and reducing cancer cell proliferation. This drug is currently being assessed in a 
phase I trial in children with recurrent or refractory solid tumours (NCT02644460) (Table 3). 
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7.3. Glembatumumab vedotin: an anti gpNMB therapy 
Glycoprotein non+metastatic melanoma protein B(gpNMB)/osteoactivin is a transmembrane 
glycoprotein that is highly expressed in various types of cancer. gpNMB is known to promote 
the invasion, migration and metastatic progression of cancer cells by modulating matrix 
metalloproteinase expression, but also by inhibiting the activation of tumour+reactive T 
lymphocytes via its binding to syndecan+4. gpNMB is also expressed by immune cells, 
including antigen+presenting cells, and may promote their adhesion to endothelial cells in an 
integrin+dependent manner. Furthermore, gpNMB decreases cell apoptosis and increases 
vascular density [154]. Recently, Roth 	
. demonstrated that osteosarcoma gpNMB and its 
targeting by the antibody+drug conjugate glembatumumab vedotin resulted in cytotoxic 
activity [155]. A phase I/II trial has been initiated (NCT02487979) in 38 recurrent or 
refractory patients (Table 3). 
 
7.4. Nanomedicine: Nab paclitaxel and MM 398 
Nanoparticles offer the possibility of encapsulating poorly soluble drugs and improving their 
half+life, bioavailability and efficacy [156]. Nab+paclitaxel is a new formulation of 
conventional paclitaxel. It is solvent free, and comes in a nanoparticle albumin+bound (Nab) 
form. Nab+paclitaxel was designed to reduce the side effects of paclitaxel and docetaxel. Its 
activity is similar to paclitaxel, and it blocks the cell cycle in G2/M by stabilising the 
microtubules and consequently blocking chromosome duplication. Nab+paclitaxel has 
demonstrated its therapeutic advantages over paclitaxel in preclinical models, and combining 
it with gemcitabine in osteosarcoma may be of great interest [157]. A phase I/II trial was 
initiated in 2013 in paediatric patients with recurrent/refractory solid tumours, including 
osteosarcoma (NCT01962103, Table 3). 
Based on similar technology, MM+398 is a stable nanoliposomal irinotecan with 
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higher cytotoxicity than the original drug. The drug was assessed successfully in a preclinical 
model of Ewing sarcoma [158] and the results provoked the initiation of a phase I trial 
(NCT02013336) in paediatric solid tumours (Table 3). 
 
8. Radiotherapy, miscellaneous trials and preparation for future investigations 
In parallel to the ongoing clinical trials centred on new drugs, complementary approaches has 
been proposed for treating high+risk located osteosarcoma and recurrent disease. Although 
osteosarcoma is considered to be a radioresistant form of cancer, radiotherapy is used in the 
treatment of osteosarcoma in high+risk locations (such as the spine) to control local and 
recurrent development of tumours, and reduce pain, especially in a palliative context [44,159]. 
Several clinical trials are currently in progress to evaluate its efficacy in controlling bone pain 
and/or its therapeutic impact (Table 4). Recently, carbon ion radiotherapy was shown to be of 
interest in the management of unresectable osteosarcomas by providing good local control of 
the tumour without unacceptable morbidity [160,161]. Complementary investigations are 
required to validate carbon ion radiotherapy as a curative option in these patients. 
Establishing biological cohorts for rare tumours takes a very long time. Such cohorts 
are nevertheless one of the key points for studying the pathogenesis of a specific disease, 
especially heterogeneous pathologies when they are associated with clinical annotations. 
Several trials have been initiated to collect biological samples from osteosarcoma patients 
(e.g. tissue, blood) and will be open until 2100, enrolling 1000 patients (trials NCT02132182, 
NCT00580385, NCT00954473, NCT00899275, Table 4). These biological cohorts are and 
will be useful for helping define various differential diagnoses (trial NCT01336803, Table 4). 
 
9. Conclusion 
Despite numerous preclinical investigations underlining the involvement of the 
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microenvironment in cancer cell proliferation and migration, the role of this tissue 
compartment in the pathogenesis of osteosarcoma is not fully understood. Based on these 
observations, several phase II trials have been proposed such as the use of Denosumab or 
zoledronic acid targeting bone niche. In fact, most of therapies described in this review such 
regulators of the immune response and consequently the immune niche should be also 
considered as clinical approaches targeting the tumour microenvironment. The heterogeneity 
of cells and molecules which composed the microenvironment of osteosarcoma, enrich the list 
of the potential therapeutic targets (e.g. blood vessels, T cells, macrophages, and bone cells) 
in addition to the master proteins that control cell proliferation or cell death. Finally, most of 
the current phase II clinical trials are based on biological processes affecting directly or 
indirectly the tumour microenvironment and will provide very useful information on the 
clinical relevance of tumour microenvironment targeting in the near future. However, the key 
to success probably lies in better characterization of the disease, as this leads to better patient 
stratification and, consequently, to personalised medicine. Better understanding of how to 
control cancer+initiating cells, characterising their genotype, and identifying their functional 
links with their close environment are the scientific/medical challenges of the next few years. 
Biological cohorts will play a part in this challenge. Ongoing phase I/II trials are important 
steps, not only for identifying new therapies with greater safety and efficacy, but also for 
better defining the role of the microenvironment in the pathogenesis of osteosarcoma and 
more specifically in the initiation of metastases. 
 
10. Expert opinion 
Osteosarcoma is the most common malignant bone tumour. Although osteosarcomas are 
chemosensitive tumours, cancer cells can become drug resistant and have a tendency to form 
distant metastases (principally in the lungs). However, despite progress in multidrug 
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chemotherapy protocols and conservative limb salvage surgery, osteosarcoma survival rates 
have not improved for more than 30 years. Transcriptomic and phosphoproteomic 
assessments have identified key intracellular signalling pathways that are activated by 
cytokines/growth factors and sustain cancer cell proliferation. These data led to the 
development of a large panel and several generations of tyrosine+kinase inhibitors, which 
were initially promising multi+target drugs. Unfortunately, most of the drugs considered had 
low efficacy in osteosarcoma patients due to the development of resistance mechanisms [55+
65]. However, many clinical trials failed to clearly evaluate their therapeutic value in the 
context of osteosarcoma with very high levels of heterogeneity. It is necessary to revisit their 
efficacy in view of the full expression profile of the tyrosine kinases of each patient. 
Sorafenib showed interesting clinical advantages, although unfortunately they remain difficult 
to analyse in the absence of an adequate control group. Complementary clinical trials are thus 
required [64]. Pazopanib [61,62], regorafenib [66] and cabozantinib (NCT02243605) may 
also be interesting therapeutic options. 
Using the tumour microenvironment as a potential therapeutic target indicates the start 
of a new era for osteosarcoma patients. Immune modulators are some of the promising drugs 
in development in osteosarcoma (see section 5). A recently set up clinical trial is studying 
whether or not to associate ipilimumab, a fully human monoclonal antibody that binds CTLA+
4 and blocks its interaction with CD80 and CD86 [162]. However, it is too early to conclude 
on any therapeutic advantages to this approach (Table 2). Mifamurtide is the frontrunner in 
the immunoregulator family, and it has been authorised after much debate in the Europe, but 
not in USA. This controversial drug was nevertheless the first to produce a significant 
improvement in survival rates in osteosarcoma. Although the effect was modest, this 
observation nevertheless identifies the concept of macrophage modulation as therapeutic 
option. In the last decade, several authors demonstrated the key role played by macrophages 
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in the pathogenesis of osteosarcoma, and, more specifically, the key point seems to be the 
balance in the M2/M1 macrophage subtype [122,123]. Since the development of mifamurtide 
[106+119], the anti+GD2 antibody [128+133], and genetically+modified T cells, vaccines have 
been proposed and are currently undergoing clinical trials. Conventional chemotherapies 
target mainly proliferating cancer cells for decreasing or slowing down the tumour 
development, and the most recent clinical approaches aimed also to control the behaviour of 
quiescent cells (e.g. cell reactivation). This is a significant modification to the philosophical 
approach used in oncology: associating “curative aspects” (e.g. killing of proliferating cells) 
and “control” of a disease  "
 the immune system (e.g. control of quiescent cancer cell 
reactivation). Radium+233 is also a promising new therapeutic agent that is retained 
preferentially in the bone matrix (tumour environment) close to the cancer cells [144+148]. 
The clinical benefits shown in the bone metastases of prostatic cancers heighten its clinical 
value. Clinical trials in progress will soon provide us with the answer. 
 Identifying and characterising early tumour recurrence and metastasis dissemination 
remains necessary for proposing better adapted therapeutic strategies. These early events 
could be characterized by biomarkers including all the biological parameters that reflect the 
recurrent disease. More specifically, they reflect all the specific signatures at the 
transcriptional and/or protein level, as well as the isolated circulating tumour cells 
characterised by a specific phenotype. Metastatic spread to specific target sites (the lungs 
and/or bones) is a clinically intractable feature of osteosarcoma’s state of dormancy 
(quiescence), evading detection whilst remaining primed to colonise the target metastatic 
organ upon induction of the right environmental cues [163+165]. 
Circulating tumour cells have also been isolated from osteosarcoma patients [166,167] 
and new technologies (e.g. microfluidic) provide an opportunity to both isolate tumour cells 
and “cancer initiating cells” from fixed paraffin embedded samples at the single cell level, 
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and better define tumour heterogeneity [168,169]. Based on the heterogeneity of 
osteosarcoma subtypes and therapeutic response, new patient stratification may be proposed 
and new multidrug targeted approaches adapted to each patient (personalised medicine) will 
emerge. The biological cohorts established will be one of the key factors in these 
developments. The gap between the new generation of drugs and conventional chemotherapy 
will be filled by new formulations of “old” drugs (such as Nab+paclitaxel) thanks to 
nanomedicine, thus improving their bioavailability, efficacy, and safety, and reducing their 
side effects [166,167].  
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Figure Legend 
 
 
 
Figure 1: Main therapeutic approaches to osteosarcoma studied in clinical trials in the 
last three decades. The tumour microenvironment plays a key role in the pathogenesis of 
osteosarcoma: it facilitates the transport of gas and nutriments to cancer cells and 
extravasation to their metastatic location (vascular niche), induces a tolerant environment 
(immune niche), and dysregulates bone remodelling (bone niche). These niches play a part in 
cancer cell proliferation, the development of quiescent/dormant subpopulations, and drug 
resistance, as well as facilitating the metastatic process. Tumour niches are a source of 
therapeutic targets both for single therapies and those combined with direct targeting of 
cancer cells.  
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